In contrast, age, hypertension, axial length, PED occurrence, GLD, and the expression levels of VEGF and VCAM-1 were negatively associated with the response to suboptimal ranibizumab treatment (P < 0.05) (Table 3). Here, VEGFA is linked to hypertensive disorder.